International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement by Zignego, Anna Linda et al.
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional 
Repository 
 
 
 
 
 
This is the author's final version of the contribution published as: 
 
Anna Linda Zignego, Manuel Ramos-Casals, Clodoveo Ferri, David Saadoun, Luca Arcaini, 
Dario Roccatello, Alessandro Antonelli, Anne Claire Desbois, Cloe Commarmond, Laura 
Gragnani, Milvia Casato, Peter Lamprecht, Alessandra Mangia, Athanasios G Tzioufas, Zobair 
M Younossi, and Patrice Cacoub on behalf of the ISG-EHCV, International therapeutic 
guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert 
statement., Autoimmun Rev. 2017 May;16(5):523-541. doi: 10.1016/j.autrev.2017.03.004  
 
 
The publisher's version is available at: 
https://www.sciencedirect.com/science/article/pii/S1568997217300575?via%3Dihub 
 
When citing, please refer to the published version. 
 
 
Link to this full text:  
http://hdl.handle.net/2318/1634212 
 
 
 
 
 
 
 
 
 
 
 
 
 
This full text was downloaded from iris-Aperto: https://iris.unito.it/  
  1 
 
International therapeutic guidelines for patients with 
HCV-related extrahepatic disorders. 
A multidisciplinary expert statement. 
 
Anna Linda Zignego, Manuel Ramos-Casals, Clodoveo Ferri, David Saadoun, Luca Arcaini, Dario 
Roccatello, Alessandro Antonelli, Anne Claire Desbois, Cloe Commarmond, Laura Gragnani, 
Milvia Casato, Peter Lamprecht, Alessandra Mangia, Athanasios G Tzioufas, Zobair M Younossi,  
and Patrice Cacoub                                                                                                                                         
on behalf of the ISG-EHCV .  
 
 
Authors affiliations:                                                                                                                                                                        
Anna Linda Zignego, MD, Laura Gragnani PhD: Interdepartmental Center for Systemic Manifestations of Hepatitis Viruses 
(MaSVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy                                                                                                  
Manuel Ramos-Casals, MD: Department of Autoimmune Diseases, ICMiD Josep Font Autoimmune Lab, CELLEX-IDIBAPS, 
Hospital Clinic, Barcelona, Spain  
Clodoveo Ferri, MD: Chair and Rheumatology Unit, Medical School, University of Modena and Reggio Emilia, Azienda 
Ospedaliero- Universitaria, Policlinico di Modena, 41124 Modena, Italy                                                                                                                                                    
Luca Arcaini, MD: Department of Molecular Medicine, University of Pavia & Department of Hematology Oncology, Fondazione 
IRCCS Policlinico San Matteo, Pavia, Italy                                                                                                                                                                
Dario Roccatello, MD: Center of Research of Immunopathology and Rare Diseases, and Nephrology and Dialysis Unit. San G. 
Bosco Hospital and University of Turin, Italy                                                                                                                                                                              
Alessandro Antonelli, MD: Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, Pisa 56126, Italy.   
Milvia Casato, MD, Department of Clinical Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185 Rome, ITALY. 
E-mail: milvia.casato@uniroma1.it 
Peter Lamprecht, MD, Klinik für Rheumatologie Oberarzt Ratzeburger Allee 160 (Haus 40)  ▪  23538 Lübeck, GERMANY. 
Tel.: ++49 (0)451 500 2368  ▪  Fax: ++49 (0)451 500 3650 E-mail: peter.lamprecht@uksh.de 
Alessandra Mangia, MD, Liver Unit,  IRCCS "Casa Sollievo della Sofferenza",  San Giovanni Rotondo, ITALY. a.mangia@tin.it 
Athanasios G Tzioufas , MD, Director Department of Pathophysiology School of Medicine University of Athens 75 M. Asias st, 
Building 16, Room 32 11527 Athens-GREECE GREECE E-mail: agtzi@med.uoa.gr 
Zobair M Younossi, MD: Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital; Beatty Liver and Obesity 
Program, Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA                                                                                                                                                                                          
David Saadoun, MD, Anne Claire Desbois, MD, Cloe Commarmond, MD, Patrice Cacoub, MD: Sorbonne University, UPMC Univ 
Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France; INSERM, UMR S 
959, Paris, France;  CNRS, FRE3632, Paris, France;  AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal 
Medicine and Clinical Immunology, Paris, France  
 
Running title: therapeutic guidelines of HCV extrahepatic disorders 
 
Key words: hepatitis C virus, HCV, extrahepatic disorders, therapeutic guidelines, autoimmunity, 
hepatitis, mixed cryoglobulinemia, vasculitis, lymphoma, neuropathy, sicca syndrome, Sjögren's 
syndrome, arthritis, diabetes, thyroid, porphyria 
 
Word count abstract: 153 
 
Word count in the text: 7.700 
 
Corresponding author:                                                                                                                                               
Prof. Anna Linda Zignego, Interdepartmental Center for Systemic Manifestations of Hepatitis Viruses (MaSVE), 
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy                                                                                                   
Azienda Ospedaliero- Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy 
Email: annalinda.zignego@unifi.it  
  2 
 
ABSTRACT  
 
 
Hepatitis C virus (HCV) is both hepatotrophic and lymphotropic virus that causes liver as 
well extrahepatic manifestations including cryoglobulinemic vasculitis, the most frequent 
and studied condition, lymphoma, and neurologic, cardiovascular,  endocrine-metabolic 
or renal diseases.  
HCV-extrahepatic manifestations (HCV-EHMs)  may severely affect the overall prognosis, 
while viral eradication significantly reduces non-liver related deaths.  
Different clinical manifestations may coexist in the same patient. Due to the variety of 
HCV clinical manifestations, a multidisciplinary approach along with an appropriate 
therapeutic strategies are required. In the era of interferon-free anti-HCV treatments, 
there are not available international recommendations for the therapeutic management 
of HCV-EHMs. This implies the need to define the best criteria to use antivirals and/or 
other therapeutic approaches. The present recommendations, based on qualified expert 
experience and specific literature, will focus on etiological (antiviral) therapies and/or 
traditional pathogenetic treatments that still maintain their therapeutic utility.  
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1. INTRODUCTION 
 
1.1. EXTRAHEPATIC MANIFESTATIONS OF HCV 
HCV is a world-wide diffused linear, single-stranded RNA virus which displays both 
hepatotropism and lymphotropism and may cause hepatic and extrahepatic 
manifestations (HCV-EHMs). HCV-EHMs include many diseases with B-
lymphoproliferative and/or autoimmune the most documented and frequent [1]. The 
recent availability of mortality rates in large cohorts of subjects confirmed the association 
of HCV infection with many extrahepatic pathological conditions including 
cardiovascular, neurologic, metabolic or renal diseases and extra-hepatic tumors [2-9]. 
The comparison between patients with persisting HCV infection and those who cleared 
the virus, showed that viral eradication significantly reduced the rate of extra-hepatic 
deaths [2, 5, 10, 11].  
HCV-EHMs can be classified according to the number and strength of supporting 
scientific data, as well as the underlying etio-pathogenic process [12]. 
The correct approach to patients with HCV-EHMs requires a multidisciplinary 
management. Specialists of different medical areas challenging with specific HCV-EHMs 
should take into account the pathogenetic role of HCV in different underlying 
pathological processes. This arises the need to define the best criteria to use antivirals 
and/or other therapeutic approaches previously standardized for virus-unrelated disease 
variants with comparable pathogenetic process. Currently, there are no international, 
multidisciplinary recommendations for the therapeutic management of HCV-EHMs  in 
the era of Interferon (IFN)-free anti-HCV treatment. Therefore, this paper will mainly 
focus on the effects of new (IFN-free) and old (IFN-based) anti-HCV treatments as well as 
non-viral therapies on the different HCV-EHMs.  
Different manifestations, being caused by the same etiologic agent, often coexist in the 
same subject. Most of available information is derived from studies carried out in 
patients suffering from cryoglobulinemic  vasculitis, CV, the prototype of   systemic HCV-
EHMs that will be considered for first. Then, the main organ-specific disorders 
(detectable or not in patients with CV) for which enough data are available will be better 
detailed, in order to give, for each condition, a picture based on different and 
complementary focuses and the most appropriate therapeutic approach. 
 
1.2. ANTI-HCV THERAPY: OLD AND NEW  
The introduction of the first, IFN-based, antiviral therapy (AVT), led to positive effects on 
several HCV EHMs, improving survival rates [13-17]. However, this treatment, even in its 
most effective combination (Pegylated(Peg)-IFN plus Ribavirin –RBV-), had limited 
efficacy. AVT options have been recently expanded with the introduction of direct-acting 
antiviral agents (DAAs),that directly target non-structural proteins with a key role in HCV 
replication.  
In 2011, the US Food and Drug Administration (FDA) approved the first generation of 
HCV NS3 protease inhibitors -also known as “-previrs”-. These molecules block the 
catalytic site of NS3, preventing the poly-protein cleavage and thus HCV replication. 
Currenly approved “-previrs” include telaprevir and boceprevir (first wave), and 
simeprevir, paritaprevir and grazoprevir (second wave). 
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Two different classes of second wave DAAs have been introduced, the NS5A and the 
NS5B inhibitors. The NS5A inhibitors block the stage of membranous genesis; they are 
also known as “-asvirs” (daclatasvir, ledipasvir, ombitasvir, elbasvir, velpatasvir). The 
NS5B polymerase inhibitors or “-buvirs”, include nucleos(t)ide analogs (sofosbuvir) acting 
as chain terminators within the polymerase catalytic site, and non-nucleotide inhibitors 
(dasabuvir), causing conformational changes and making the polymerase ineffective. The 
first generation of DAAs needed the combination of Peg-IFN and RBV and prolonged 
treatments, while the currently available therapeutic schedules are based on different 
IFN-free (sometimes RBV free) DAA combinations, with shorter therapy duration 
(generally 12 to 24 weeks), minimal side-effects (Table 1) [18], and efficacy approaching 
100% [18]. The correct choice of these regimens takes into account virus-related features 
(i.e., HCV genotype/subtype) and/or host-related features (i.e., presence/absence of 
severe liver disease, low creatinine clearance, drug-drug-interactions). These new drugs 
are providing the opportunity for a dramatic change in the anti-HCV therapeutic 
approach, eradicating HCV with high efficacy without IFN related side effects. Main 
international guidelines are in agreement on the opportunity to recommend AVT to all 
HCV infected patients without a short lifetime expectancy (i.e., 
http://www.hcvguidelines.org/full-report-view ). However, universal treatment may not 
be scaled up in many countries for lack of financial resources and/or of health care 
infrastructure and indications to prioritization concerning some HCV-EHMs, essentially 
based on increased risk of mortality and morbidity have been defined 
(http://www.easl.eu/research/our-contributions/clinical-practice-
guidelines/detail/easl-recommendations-on-treatment-of-hepatitis-c-2016 and 
http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ ; Table 2). 
 
2. METHODS  
The production of therapeutic guidelines for HCV-EHMs was conceived and organized by 
the International Study Group of Extrahepatic Manifestations Related to Hepatitis C 
Virus Infection (ISG-EHCV), which is a multidisciplinary international network of 
recognized experts in this field. In order to provide an homogeneous therapeutic 
approach to patients with HCV-EHMs, the ISG-EHCV convenor and co-convenors invited 
other ISG-EHCV members on the basis of their well-known expertise in the field of each 
HCV-related manifestation. This task force initially gathered via e-mail and successively 
via teleconference meetings for the discussion of different issues. A systematic review of 
the literature specifically correlated to the different HCV-EHMs was done, representing 
the backbone of the paper  [19] .    
 
3. RESULTS: THERAPEUTIC APPROACH TO THE SINGLE HCV-EHMs 
The first, essential step for a correct therapeutic approach to HCV EHMs is represented 
by an accurate general assessment of patients and diagnosis of single HCV-EHMs, as 
previously described [19]. 
The therapeutic approach to the main HCV-EHMs are described in the following 
paragraphs  by starting with the CV; since the majority of the studies are focused on 
patients with CV, this systemic disorder represents a precious model for the analysis of 
the effects of etiologic therapy on HCV EHMs.  
 
3.1. CRYOGLOBULINEMIC VASCULITIS (CV) 
  5 
 
CV is the most frequent and largely investigated HCV-EHM [1, 12, 20, 21]. A detailed and 
complete description of this complex disease, in its different aspects, will be the object of 
a dedicated paper  by our study group (see Saadoun et al, manuscript in preparation). In 
the present paper, the essential aspects justifying the most opportune therapeutic 
approach will be considered. 
CV is a both autoimmune and lymphoproliferative disease (LPD), clinically benign 
(although sometimes with a severe presentation), but possibly evolving into lymphoma 
[20, 22-24]. The pathological substrate of CV is the HCV-driven B-cell 
lymphoproliferation and the consequent production of cryo- and non-cryoprecipitable 
immune complexes, in turn responsible for vasculitic manifestations. Mixed 
cryoglobulins (CGs) are immune complexes that reversibly precipitate when the 
temperature is lower than 37°C [12, 22, 25, 26] and that consist of IgM with rheumatoid 
factor (RF) activity [mono- or oligo-clonal in type II mixed cryoglobulinemia (MC), or 
polyclonal in type III MC] and polyclonal IgGs [27]. Most CV patients are HCV positive 
(70–90%) and conversely 40–60% of HCV infected patients produce CGs of whom 5–30% 
with symptomatic CV [12, 22, 25, 26]. Since HCV infects about 170 million individuals 
worldwide, the number of patients at risk for developing CV is substantial. The syndrome 
is characterized by the typical clinical triad - purpura, weakness, and arthralgias -, low 
complement C4 fraction serum level and various visceral organ involvement, including 
renal, neurological, cardiac or digestive disease. According to the vasculitis severity, 
patients may manifest mild/moderate disease (i.e., purpura, articular involvement, mild 
sensory neuropathy), severe disease (i.e., extensive/ulcerative skin disease, severe 
sensory-motor neuropathy, glomerulonephritis with impaired renal function, 
gastrointestinal involvement) or life-threatening conditions (i.e., rapidly progressive 
glomerulonephritis, CNS involvement, intestinal ischemia, alveolar hemorrhage).   
 
Etiologic treatment  
IFN-based AVT  
After the first, pioneering studies using recombinant IFNα in 1993 [13, 28-30], AVT 
followed the evolution of hepatitis C treatment with some differences (i.e., in the drug 
doses/duration, combination with non-viral therapies) (Table 3), essentially due to the 
possible side-effects of IFN and/or RBV therapy (i.e. IFN neurotoxicity and myelo-
inhibitory action and RBV hemolytic effects). The main steps in IFN-based AVT were 
represented by IFN monotherapy, its combination with RBV, and the combination of 
pegylated-IFN (PegIFN) and RBV that represented the standard of care for about fifteen 
years. The virological and clinical results progressively improved, but not the type or 
rates of side-effects. Clinical remission was clearly correlated with virological response 
(sustained virological response –SVR-: prolonged negative viremia), although with some 
discordant data [31-36], including the persistence of CV in rare patients with SVR. 
However, this rare situation was generally transient or related to severe sequela of CV or 
the presence of a B-cell NHL. Possible explanations included the evolution to a late stage 
when the B-cell proliferation became independent from the etiologic agent, with 
persistence of the pathogenetic B-cell clone expansion and the evolution to overt 
lymphoma (see Figure 1). Also, a too advanced tissue damage  could affect a full 
functional restoration, for example for a severe sensory-motor peripheral neuropathy. 
Therefore, a prompt and early HCV eradication was reputed essential. The complexity of 
such autoimmune/lymphoproliferative disorder suggested a sufficiently long follow up 
  6 
 
after HCV eradication to evaluate its real effects on CV symptoms. In a prospective and 
controlled study including more than 400 HCV infected patients with/without CG and 
with/without CV, after a mean follow-up of 8 years, all CV symptoms persistently 
disappeared in 57% of SVR patients; some signs and/or symptoms persisted in the 
remaining patients, although improved. All virological non-responders were also clinical 
non-responders, despite of a transient improvement in some cases. Furthermore, the CG 
was a negative prognostic factor of virological response [17]. In consideration of all 
available data, the IFN-based AVT was recommended as the first-line option in mild to 
moderate CV [37].  
The introduction of first-generation DAAs that were associated to Peg-IFN and RBV 
increased SVR rates, but also the side-effects. Saadoun et al described their safety and 
efficacy in 30 CV patients [38], where 67% of patients were complete clinical and 
virological responders while severe side effects occurred in 47%. Another study confirmed 
the good efficacy of such combination in 22 cryoglobulinemic subjects, with a CG 
disappearance in 86% but a lower SVR rate in cryoglobulinemic patients than in patients 
without mixed cryoglobulinemia (23.8% vs 70%, p=0.01)[39]. Stine et al. in small case 
series of CV patients treated with triple AVT (Peg-IFN plus RBV plus sofosbuvir or first 
generation DAAs) suggested a longer treatment for cirrhotic patients, apparently more 
refractory to clear CGs [40, 41]. 
 
Interferon-free AVT (Table 4) 
Limited, but essentially concordant data, are available regarding patients with CV. The 
first study reported the effects of a sofosbuvir/RBV combination for 24 weeks in 24 CV 
patients [42]; SVR was scored in 74% patients, with high rate of clinical response (87%) 
and low rates of serious adverse events [42]. The rate of SVR was that expected from 
used AVT protocols. Sise et al., using sofosbuvir-based combinations in 12 CV subjects, 
obtained an improvement in renal function with or without immunosuppressant and 
SVR12 in 83% [43]. An interim analysis, mostly based on the combination of 
paritaprevir/ritonavir, ombitasvir, plus dasabuvir, showed a cryocrit decrease and a 
clinical response even during treatment [44]. The clinical improvement rate gradually 
increased from the inhibition of viral replication, end of treatment and SVR12 [45]. A very 
recent prospective study assessed efficacy and safety of sofosbuvir-based individually 
tailored therapy, in a cohort of 44 consecutive CV patients (median after treatment 
follow-up: 42 weeks, range 27-53). All patients obtained viral eradication and an overall 
100% rate of clinical (complete or partial) response at week 24 post-treatment. 
Interestingly, a progressive increase of complete response rate over time, confirmed 
previous, preliminary observations. Recently, Kondili et al. reported results of a 
nationwide Italian study, describing the disappearance or improvement of more than 
50% of CV symptoms in 31/37 (84%) patients after DAA [46]. Available data suggest that 
IFN-free AVT is safe, generally well tolerated and effective in CV patients.   
 
Non-etiologic treatment 
The non-etiologic therapy of CV remains useful for severe patients before and during 
AVT, and sometimes after AVT for patients with persistent symptoms. However, it is not 
recommended as maintenance therapy after complete symptom remission, even when 
cryocrit, abnormal RF and/or complement levels are still altered.  
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This approach is usually based on anti-inflammatory drugs [i.e., glucocorticosteroids 
(GCs)], immune-suppressants [i.e., cyclophosphamide (CTX)], azathioprine, biological 
drugs [rituximab (RTX)], and analgesics, including non-steroidal anti-inflammatory drugs 
(NSAIDs). Furthermore, low-antigenic diet and apheresis can be helpful to decrease 
serum CGs levels, particularly in case of renal involvement. 
These measures should be used considering the potential effects on viral replication and 
liver damage; the administration during DAA therapy, requires a mandatory evaluation of 
the drug-drug interactions.  
GCs are commonly used to control inflammation and pain [47-54]. Low-medium doses of 
GCs (0.1-0.5 mg/kg/day) usually control mild to moderate symptoms, whereas high-dose 
pulse therapy (1–10 mg/kg) is commonly indicated to manage severe and acute 
conditions, specifically renal failure, neurologic manifestations or hyperviscosity 
syndrome [37, 47-50, 55]. The risk of multiple side-effects should be considered in case 
of GCs long-term administration [49-52, 56]. In particular, in case of severe liver damage, 
the effects on viral replication, electrolyte balance (ascitic decompensation) and lipid 
metabolism (liver steatosis), have to be evaluated. The prolonged treatment with GCs, 
although common in clinical practice, has preferably to be avoided or at least reduced. 
Colchicine has been used as steroid-sparing agent to reduce Ig secretion [57, 58]. It 
could have favorable transient effects on purpura, weakness, and leg ulcers when 
administered at dose of 1 mg/day for 6–48 months. The use is limited by the risk of 
gastrointestinal side-effects [57]. The low-antigen-content diet aims to restore 
phagocyte activity and modify the composition of circulating immune-complexes. In mild 
to moderate CV, this diet was shown to reduce symptoms and laboratory signs [37, 59]. 
Its use has been proposed as a supportive treatment for all symptomatic patients [54]. 
Analgesic drugs and NSAIDS are used to obtain a relief and reduce the GCs 
administration, especially in patients with peripheral neuropathy. Acetaminophen, 
gabapentin or pregabalin, opioids, and amitriptyline are the most used. The analgesics 
and NSAIDS administration is tailored on specific CV symptoms and on liver disease 
degree (especially for NSAIDs and benzodiazepines).  
 
Other approaches have been shown to be very effective in severe CV; among them, 
Rituximab (monoclonal antibody against the B-cell specific CD20 antigen) has a 
prominent role [41, 60]. RTX binding to CD20 causes a B-lymphocytes depletion thus 
justifying the extensive use in B-lymphoproliferative disorders and severe autoimmune 
diseases. The safety and efficacy of RTX monotherapy in CV were clearly shown [61-82]. 
RTX is especially recommended in case of HCV related CV with severe clinical 
manifestations, preferring it to more conventional treatments . RTX can improve various 
manifestations of CV, including skin symptoms (purpura and ulcers) [61, 62, 64], 
fatigue, arthralgias/arthritis, glomerulonephritis (GN) and, peripheral neuropathy in a 
relevant number of cases (75-90%%) [61, 62, 64-66, 75], including some life-threatening 
complications such as hyper-viscosity syndrome [37, 61-82] or gastrointestinal vasculitis 
[68-70]. It has been reported that RTX is able to restore some CV-related immune 
abnormalities; it can decrease cryocrit, improve RF and C4 levels [83], and induce the 
disappearance of bone marrow B cell clonal expansion. Furthermore, RTX has a steroid-
sparing effect [61, 65, 84]. Most studies used the standard hematological treatment 
schedule (375mg/m2 in four consecutive weekly infusions). Lower doses and/or shorter 
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treatment have been also reported, i.e., 1g every two weeks for two infusions or 250 
mg/m2 in two administrations [82].  
Since RTX is not active on B-cell progenitors, the effect is transitory with variable 
duration of the clinical effect (from 3-4 months to more than 12 months); long-term 
responses usually prevail. Before IFN-free AVTs, repeated treatments [61, 64, 65, 68] and 
maintenance regimens were necessary, especially in patients with nephritis or severe 
abdominal vasculitis [65, 67, 68], because RTX has only a transitory effect and the viral 
trigger (HCV) was still present. The relationship between etiologic treatment and RTX is 
of interest. In the IFN era, most studies on RTX have been performed on patients who 
had failed or were not eligible for AVT, even if some authors suggested a combined RTX 
plus AVT in patients with severe manifestations (generally using RTX before AVT) [32, 65, 
85]. The effect of RTX treatment made eligible to IFN-based AVT some previously 
excluded patients [79]. In two controlled clinical trials, the combination of RTX with AVT 
showed a synergistic effect [69, 83, 85], being more effective in CV manifestations than 
AVT alone, particularly when a kidney involvement was present [86, 87]. The AVT after 
RTX compared with RTX alone increased the relapse-free survival [88, 89]. In most 
studies the combination was sequential, starting with RTX or AVT depending on the 
condition of the patient while, in some others, both therapies were administered 
concomitantly. 
Data about combined RTX plus DAA-based therapy are still scarce [41, 60]. However, it 
is conceivable to figure out promising successes of combination with IFN-free schedules. 
The exact place of RTX in the field of CV has to be more precisely defined. With the 
approval of recent DAAs IFN-free combination, which proved very highly and rapidly 
effective on viremia, we will have to define in the next future the remaining place of RTX. 
For example, as a  first-line option for severe and life-threatening conditions needing 
urgent intervention and a second-line option for those maintaining significant symptoms 
after SVR.  
 
3.2. LYMPHOMA  
In 1994, a high prevalence of HCV infection in Italian patients with lymphoma was first 
reported in limited cohort of patients [90, 91]. In the last two decades, several evidence 
proved the association between HCV infection and the occurrence of hematologic 
malignancies, mostly B-cell non-Hodgkin’s lymphoma (B-NHL) [92, 93]. A clear gradient 
of HCV-related lymphoma from North to South was also shown as for HCV infection [1, 
94]. Dedicated meta-analyses were able to confirm (although with different degrees), an 
increased risk of lymphoma in HCV infected subjects [93, 95-98]. A confirmation derived 
also from the highly significant reduction in the lymphoma risk found as a result of 
sustained viral eradication [10, 17]. This also suggested that AVT could represent a 
preventive measure for the development of lymphoma. 
The association did not involve a specific histopathological type of B-NHL, although some 
of them appear more frequently related to HCV infection. HCV was initially linked to 
indolent NHL, then the association with aggressive subtypes was also shown. Marginal 
Zone (MZL), Diffuse Large B Cell (DLBCL) and Lymphoplasmacytic lymphomas 
(Waldenstrom’s macroglobulinemia, WM) were the most frequent reported B-NHL in HCV 
infected patients [93, 99, 100].  
 
Etiologic treatment and its place with respect to non-viral treatment 
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Since the first report in 2002 by Hermine et al in HCV-positive splenic lymphoma with 
villous lymphocytes [101], a large series of evidence demonstrated that IFN-based AVT is 
able to induce hematological response along with virological clearance in patients with 
HCV-associated low grade lymphomas (especially MZL). A recent meta-analysis on 20 
studies evaluated the efficacy of an IFN-based AVT in 254 patients with HCV-associated 
B-NHL [24]. Lymphoma response rate was 73% in all patients and up to 83% in SVRs. A 
better lymphoma response was shown in marginal zone compared to non-marginal zone 
lymphoma (81% vs.71%). Preliminary data with IFN-free regimens  in HCV-associated 
LPDs suggest their anti-lymphoma activity too [102]. 
On this basis, AVT should be considered the first-line approach in HCV-associated low 
grade lymphomas if there is no immediate necessity of a conventional treatment (i.e., 
systemic symptoms, bulky disease or symptomatic splenomegaly), irrespectively of liver 
damage (generally mild) [103], as also recommended by recently updated hematological 
(ESMO [104] and NCCN [105]) and hepatology (EASL [106]) guidelines.  
Among HCV-associated aggressive lymphomas, DLBCL is the most frequent type [107]. 
An immediate conventional therapy is required, being the immunochemotherapy scheme 
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) the 
standard choice [108]. The observation of a dissociation between HCV-RNA levels and 
liver injury after immunochemotherapy, suggested that liver impairment is not directly 
related to an enhanced HCV replication [109]. 
IFN-based AVT, when administered in combination with immuno-chemotherapy 
significantly increased hematologic toxicity [110], whereas, during the post-
chemotherapy follow-up was associated to a better outcome [111]. HCV eradication by 
IFN-free AVT after completion of immunochemotherapy should also be recommended 
with the aim to eliminate the lymphoma trigger and potentially reduce the risk of 
lymphoma relapse [107, 112]. Recently, it has been also reported that treatment of HCV 
infection in transplant recipients improves both lymphoma and liver disease outcomes 
strongly suggesting  the use of IFN-free regimens following close monitoring for potential 
drug-drug interactions [113]. Concurrent administration of DAAs and immuno-
chemotherapy should be tested in prospective trials, although no particular overlapping 
toxicities can be predicted. No specific recommendation is possible for HCV-positive 
DLBCL relapsed or refractory to a first-line treatment; however, high-dose chemotherapy 
with autologous support seems feasible in this setting [114, 115].  
 
3.3. HCV-ASSOCIATED KIDNEY DISEASES 
The association between HCV and chronic kidney disease (CKD) is undoubted. Several 
large surveys based on clinical databases suggested a significant impact of HCV on 
prevalence and incidence of CKD [116, 117]. A large case-control study [118] showed a 
significant association between HCV infection and membrano-proliferative 
glomerulonephritis (MPGN). In addition, HCV positive subjects showed a significantly 
higher prevalence of renal insufficiency (serum creatinine ≥1.5 mg/dl) after adjusting for 
influencing variables [119-121].  
As previously observed, cryoglobulinemic nephropathies represent the most frequent 
conditions, with type I MPGN the most common form. Membrano-proliferative 
glomerulonephritis without cryoglobulinaemia, membranous nephropathy, and 
mesangioproliferative glomerulonephritis are rare pictures. Occasional observations of 
focal segmental glomerulosclerosis, fibrillary or immunotactoid glomerulopathies, or 
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thrombotic microangiopathy have been also rarely reported [12].  MPGN can be diffuse or 
focal (more or less than 50% of involved glomeruli), and it is characterized by duplication 
of glomerular basement membrane (GBM), GBM interposition by mesangial cells 
(especially monocytes), sub-endothelial and mesangial deposition of immune reactants, 
mesangial proliferation with leukocyte exudation, endoluminal hyaline pseudo-thrombi 
(corresponding to cryoglobulin precipitates) and, rarely, extra-capillary proliferation.  
A correct therapeutic approach involves the early evaluation of activity/severity of renal 
damage and its tendency to rapidly evolve, with individual tailoring of treatment.. As an 
example, in case of cryoglobulinemic nephritis, the distinction between a diffuse or focal 
MPGN and mesangial glomerulonephritis (the main glomerular patterns of 
cyoglobulinemic nephritis) appears critical [122]. In fact, the main histopathological 
changes characterizing MPGN may improve with a strong immunomodulating treatment, 
including GCs and/or immunosuppressive agents and plasma exchange in escalation 
protocols. Consequently, these measures should be the first-line therapeutic approach, 
considering AVT after improvement and stabilization of the condition. GCs should be 
given only at the onset of the vasculitis process and then rapidly tapered until 
discontinuation (see below). By contrast, the use of AVT, especially DAA-based, should 
be recommended as first-line approach in case of mesangial glomerulonephritis, where 
exudation, endo-capillary and extra-capillary proliferation, and endo-luminal thrombi are 
almost invariably absent and the lesions are likely to be self-limiting and spontaneously 
regressing. Significant poor prognostic variables (i.e., age, male gender, creatinine and 
proteinuria at the time of renal biopsy, number of clinical relapses, and poor blood 
pressure control) should also be taken into account [122]. Kaplan–Meier survival curves 
are worsened by creatinine value >1.5 mg/dL (133 μmol/L) at the time of renal biopsy. 
Cardiovascular disease is the leading cause of death (over 60 % of cases). 
Etiologic treatment 
The large majority of data about AVT have been derived from patients with CV. Several 
evidences justify the interest for HCV eradication in the setting of kidney disease. These 
include, first, the consistent role of the infection in conditioning the disease outcome 
(especially evident in kidney transplanted patients), as well as the significantly higher 
prevalence of HCV infection in nephropathic patients in comparison with the general 
population. Additional data arise from studies showing the positive effect of viral 
eradication on CKD and related mortality rates. In a recent population-based cohort 
including patients with diabetes mellitus [5], the 8-year cumulative incidence of end 
stage renal disease was significantly higher in HCV infected untreated than in the AVT 
treated and uninfected cohorts (p<0.001). In the past years CV patients showed greater 
renal response rates when treated with a combination of RTX and PegIFN plus RBV 
compared with PegIFN and RBV alone [86, 87]. The only availability of IFN-based AVT 
have been a limitation to the etiologic approach. However, the Kidney Disease Improving 
Global Outcomes (KDIGO) Group recommended in 2008 to treat patients with flares of 
CV MPGN with AVT, even if IFN-based; RBV dosage should be closely monitored due to 
the risk of anemia [123]. No doubt such recommendations are today obsolete. Recently, 
IFN-free AVTs, due to their good tolerance profile (despite some concerns regarding 
pharmacokinetics and safety in patients with severe renal failure) [124], will probably 
positively change the epidemiology of HCV-associated nephropathy. Sise et al, observed 
on a small cohort of 7 patients with CV and glomerulonephritis treated with IFN-free AVT 
that a SVR12 was correlated to an improvement in serum creatinine and a reduction in 
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proteinuria [43]. In other recent observations the improvement of kidney disease in 
virological responders was progressively more evident from the inhibition of viral 
replication to 12 or 24 weeks after therapy [17, 44, 125].  
Non-etiologic treatment 
Immunosuppression is still regarded as the first-line intervention in CV if renal 
involvement is severe/rapidly progressive . In these cases, AVT is usually insufficient to 
rapidly control renal disease and has also been shown to be detrimental in case of IFN 
and/or RBV. The conventional high-dose GCS, plasmapheresis, and, in more severe 
cases, cytotoxic therapy, have been commonly administered in patients with 
cryoglobulinemic nephritis. Patients usually require multiple courses because of 
recurrent flares even after a prolonged remission. The combination of CTX (1.5–2 
mg/kg/day given orally for 3 months, or 0.5–1 g administered intravenously every 2–4 
weeks) in association with oral GCs (0.5–1 mg/kg/day for 1 month with subsequent 
tapering by 2.5–5 mg/week), often preceded by 3 pulses of 10–15 mg/kg 
methylprednisolone, represents a common therapy in the severe forms of 
cryoglobulinemic nephritis. The less toxic mycophenolate mofetil, given for 6 months, can 
be an alternative option to CTX. Plasma exchange, especially double-filtration 
plasmapheresis, continues to be successfully used in escalation protocols for rapidly 
progressive glomerulonephritis. RTX has been successfully used alone, in combination 
with GCs and also with AVT in several studies. Detailed renal outcomes can be achieved 
on over 200 patients; renal response (complete plus partial) was 70-90%. 
Glomerulonephritis usually improves within 3 months; complete healing takes longer. No 
substantial adverse effects of RTX on HCV viremia were observed. However, a flare of CV 
has been reported in patients with high CG level receiving high doses RTX (1000 mg), 
suggesting that in such patients the protocol should start with plasmapheresis and then 
use the classical schedule (375mg/m2 per infusion) [126]. In a study on a large cohort of 
biopsy-proven severe cryoglobulinemic nephritis followed for 6 years after the 
administration of the 4 +2 × 375 mg/m2 protocol, the survival rate was 75% at 6 years 
and the probability of remaining symptom-free for 10 years was of about 60% [127]. 
 
3.4. NEUROPSYCHIATRIC DISORDERS AND HEALTH-RELATED QUALITY OF LIFE 
(HRQOL)  
Neuropsychiatric disorders. HCV is associated with various neuropsychiatric disorders 
[128]. The prevalence of depression is higher in HCV infected patients than in the general 
population (59% versus 21%) [129]. Approximately 60% of HCV infected patients suffer of 
sleep disorders [130], fatigue (prevalence: 50–67%) [131] and mood disorders that, in 
turn, negatively and independently affect the quality of life [132, 133]. Cognitive 
impairment was also described [134, 135]. These morbidities did not completely correlate 
with liver disease severity, suggesting a direct association with HCV [136, 137]. It has 
been hypothesized that the virus enters the Central Nervous System (CNS) infecting 
CD68+ peripheral cells, microglia precursors [138]. Therefore, viral proteins could exert a 
neurotoxic effect [139, 140]. The increased expression of cytokines, such as TNF-alpha 
and IL-8, could also play a role at local and systemic level [141, 142]. Furthermore, HCV 
may directly affect the serotonergic and dopaminergic neurotransmission with resultant 
depressive symptoms [143]. Rarely, neuropsychiatric manifestations are secondary to 
HCV-induced CV with abnormal brain MRI [144]. 
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Health related quality of life (HRQoL). Naive HCV-positive patients are characterized 
by poor HRQoL compared to the general population [145-147]. Based on the Short Form 
36 (SF-36) Health Survey questionnaire, they consistently show deficits in several 
domains, particularly those involving physical role, general health and vitality [148-150]. 
In turn, poor HRQoL can lead to difficulties with interpersonal relations, decreased 
feelings of self-value and utility, and depression, with a decreased ability both at work 
and at home, and obvious cost implications.  
 
Etiologic treatment 
The relationship between mood disorders and IFN-based AVT has been widely discussed. 
IFN side-effects increased with higher doses and longer therapies [151]; the onset of 
depression has been observed in 30%-70% of treated patients [152, 153]. IFN was also 
associated with sleep disturbances, anxiety, cognitive disorders (up to 50%), while 
maniac and psychotic symptoms were less frequent (3% of patients). Irritability is also an 
important side-effect, involving approximately 75% of patients during therapy. 
The HRQoL records during IFN and RBV therapy are usually low and the average scores 
of the SF-36 worsen rapidly, in particular, in the physical role, emotional role, vitality 
and social functioning [154]. Consequently, before to initiate an IFN-based treatment, a 
psychiatric counseling, should be recommended [151]. In some cases, the management 
of symptoms requires a therapy including pharmacological support with antidepressants 
(particularly selective serotonin reuptake inhibitors) or with benzodiazepines [155]. The 
possible co-morbidity with substance abuse limits the use of these drugs, for the risk of 
rebound effect, tolerance and dependence. In most instances the neuropsychiatric 
symptoms are resolved after IFN discontinuation. After SVR, the HRQoL scores improve 
compared to baseline values [156]. 
The effect on HRQoL of IFN-free treatment has been studied by Younossi and colleagues 
in patients treated with sofosbuvir-based combinations with or without RBV [154, 157, 
158]. Compared to placebo, these treatments were not associated with HRQoL 
impairment and the SVR correlated with HRQoL improvement [154]. Nevertheless, the 
presence of RBV still seems to poorly influence HRQoL, partly due to hemoglobin 
reduction: patient-reported outcomes (PRO’s) are higher in RBV-free regimens [158].  
In conclusion, compared to IFN-based, IFN-free AVTs, cause minimal reduction in PROs 
during therapy and improvement of vitality and fatigue at SVR12 [158]. Although few 
specific drug-drug interactions have been described between psychotropic molecules and 
DAAs (i.e. between Ritonavir and Carbamazepine, Nefazodone and Triazolam) [159] a 
cautious approach is needed since pharmacokinetic interactions can induce increase or 
reduction of one or both drugs, with toxicity or under-dosing risks.  
 
3.5. PORPHYRIA CUTANEA TARDA (PCT)  
PCT is characterized by low activity of uroporphyrinogen decarboxylase (URO-D) involved 
in heme synthesis. It can be classified as familial or sporadic. In the acquired, sporadic 
form (type I PCT) a 50% deficient activity of URO-D in the liver leads to an overt 
manifestation; this can be the consequence of a trigger such as HCV, alcohol and liver 
toxins [160-162]. Iron overload (hepatic siderosis) is a critical pathogenetic event, 
disrupting the enzymatic activity of URO-D by inducing the formation of an intracellular 
inhibitor [163]. The relationship with HCV infection is supported by epidemiological 
associations, especially in some geographical areas [164]. However, the absence of 
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altered porphyrin metabolism in HCV-positive patients without PCT, argues against a 
direct role of HCV. PCT manifestations include typical cutaneous lesions in sun-exposed 
areas, photosensitivity, skin fragility, facial hypertrichosis and late-stage sclerodermoid 
plaques. 
 
Etiologic treatment 
The indirect role played by HCV infection and the sensitivity to the iron deposits due to 
the hemolytic effect of RBV, may explain the controversial results reported with  
IFN/RBV AVT. On one hand, an effective AVT may potentially improve clinical and 
laboratory manifestations of PCT, especially when preceded by therapeutic phlebotomy 
[162]. On the other hand, a worsening and  a new-onset PCT have been reported in some 
cases [165], possibly due to the RBV-induced hemolytic anemia, further increasing liver 
iron excess. It is expected that the management of this condition could benefit from a 
viral eradication with both IFN- and RBV-free regimens, but no data are available today. 
It is also conceivable that DAAs already known to cause photosensitivity have to be 
avoided. 
 
Non-etiologic treatment 
The standard of care for PCT includes photo-protection, anti-malarial drugs (chloroquine) 
and phlebotomy, the latter to reduce hepatic iron stores [163].  
 
3.6. LICHEN PLANUS 
Lichen planus (LP) is an inflammatory disorder involving the skin and the oro-genital 
mucous membranes. Oral LP is the most studied phenotype in the setting of HCV 
infection [166]. The association with HCV has been widely described [167] and it has 
been suggested that HCV-LP is the result of a T-cell mediated autoimmune reaction [168, 
169]. Conflicting data may depend on geographical and/or methodological factors, with 
genetics (HLA-DR-associations), age and IFN-based AVT also playing a role [163].  
 
Etiologic treatment 
IFN-based AVT should be avoided. In fact,  type-1 IFNs are a major driver of lichenoid 
inflammation [170] and IFN-based AVT may negatively influence established LP or induce 
the onset of lichenoid lesions. This increases the interest for studies on IFN-free AVT, 
although no data are available at present.  
 
Non-etiologic treatment 
Treatment of LP is based on a step-wise approach with the use of topical and/or systemic 
immune-modulating agents, tailored on disease’s characteristics [171]. Systemic 
treatment is indicated in severe/advanced disease, and includes retinoids (acitretin), 
GCs, methotrexate, and cyclosporine [172]. In HCV-positive LP it should be performed 
considering the severity of liver disease: a strict follow-up of the main liver function tests 
(LFTs) should be performed as well as an accurate evaluation of the possible drug-drug 
interactions between DAAs and non-etiologic drugs (i.e., cyclosporine). 
3.7. HCV-ASSOCIATED ENDOCRINE DISORDERS 
The main endocrine HCV-EHDs are represented by thyroid diseases and type 2 diabetes 
mellitus (T2DM) [19, 127]. Gonadal dysfunctions are reported in male HCV-infected 
individuals [19], but data on specific therapies are lacking. 
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THYROID DISORDERS 
Autoimmune thyroid diseases are among the most frequent endocrine  disorders in HCV 
infected patients [173]. They result from a dysregulation of the immune system leading to 
T cell-mediated organ-specific autoimmunity. In 80-85% of cases, circulating thyroid 
autoantibodies are detected; thyroid ultrasonography and cytology can help in the 
diagnosis. A thyroid dysfunction (mainly hypothyroidism) is present in about 30% of 
patients [127]. In a recent meta-analysis, the prevalence of anti-thyroglobulin antibody 
(AbTG), anti-thyroid peroxidase antibody (AbTPO), anti-thyroid microsomal antibody 
(ATMA) and hypothyroidism were higher in HCV positive patients than in controls [174]. 
An even higher prevalence of thyroid dysfunction was observed in HCV-CV patients [175, 
176]. 
A higher prevalence of papillary thyroid cancer has been found in chronically HCV-
infected patients, particularly in those with autoimmune thyroid diseases [173]. In a 
recent wide cohort study, anti-HCV seropositivity was associated with multivariate-
adjusted hazard ratio for thyroid cancer [6]. 
 
Etiologic treatment 
IFN-α therapy is a well-known risk for the development of autoimmune thyroid diseases 
and thyroid dysfunctions [177]. Thyroid disease developed in up to 25-30% of HCV 
patients during Peg-IFN/RBV treatment, and about half of these patients need thyroid 
treatment [178]. Most patients with IFN-α-induced hyperthyroidism present Hashitomoto 
disease and have a transitory hyperthyroidism, while a minority of them develop Graves' 
disease. In patients with long-term hyperthyroidism and Graves' disease, radioiodine 
therapy was effective and well-tolerated [179]. 
A recent study retrospectively analyzed data from Graves' disease patients with or 
without HCV infection treated with IFN-α or methimazole (MMI), respectively. Results 
suggested a more favorable course of Graves' disease in HCV patients treated with IFN-α, 
than in uninfected patients [180]. 
Assessment of thyroid-stimulating hormone (TSH) and thyroid autoantibodies at baseline 
and close monitoring of thyroid function during Peg-IFN/RBV therapy are necessary for 
early detection and management of IFN-induced thyroid disease [181].  
High values of the circulating prototype Th1 chemokine (C-X-C motif) ligand 10 
(CXCL10), are present in HCV CHC and CV patients with autoimmune thyroid diseases 
[182]. However, lower pretreatment serum CXCL10 levels were associated with thyroid 
disease, and thyroid disease prevalence increases in HCV female patients and patients 
who are positive for AbTPO at baseline, treated with PEG-IFNα-2a/RBV [183]. In another 
study, thyroid disease with high TSH levels has been shown to be associated with good 
response to Peg-IFN/RBV [184]. 
Currently, scarce data exist about IFN-free AVT. The possibility of interactions of Levo-
thyroxine (L-T4) (the common treatment for HCV autoimmune thyroid diseases) [185] 
with DAAs suggest an accurate tailoring of treatment schedules [186]. 
 
Non-etiologic treatment 
Treatment of thyroid disease (hypothyroidism/hyperthyroidism) or thyroid cancer should 
be performed when needed, according to the current specific guidelines [187]. 
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TYPE 2 DIABETES MELLITUS 
Epidemiological data support the association between HCV infection and T2DM [19, 
188]. In a review of 102 studies, diabetes was one of the most common HCV-EHM (15% 
of patients) [189] with important implications for outcome, prevention and treatment. It 
was shown that T2DM, with or without insulin resistance (IR), reduces responsiveness to 
IFN-based AVT [190, 191] and was associated with higher risk of developing cirrhosis 
and hepatocellular carcinoma (HCC), even after viral eradication [192, 193].  
HCV may induce IR through multiple mechanisms [194]. In turn, IR plays a crucial role 
in fibrosis progression, and has a negative impact on AVT responses [195]. Obesity and 
physical inactivity also cause hyperinsulinemia, and accelerate HCV-induced damage 
[196]. HCV-induced IR can also lead to arterial hypertension, hyperuricemia, and 
atherosclerosis, resulting in increased cardiovascular mortality. The interaction of T2DM 
with CHC and “non-alcoholic fatty liver disease” (NAFLD) may result in a "vicious circle", 
that can lead to an increased risk of all-cause mortality and liver-related and 
cardiovascular complications [197, 198]. In turn, HCV infection in patients with T2DM 
may also increase the proportion of DM-related kidney complications [199].  
Etiologic treatment 
Most available data are concerning IFN-based AVT. Clinical trials reported improvement 
of glucose metabolism [200] and  reduction in the T2DM incidence after HCV eradication 
[201]. Concerning DAAs, a case report showed improved glycemic control after a 
successful sofosbuvir-based regimen in a patient with poorly controlled T2DM [202], 
while other analyses showed a marginal impact of IFN-free regimens on hemoglobin A1c 
[203]. T2DM was also a negative predictor of patient-reported outcomes [204]. Further 
studies are needed to correctly evaluate the AVT influence on the long-term course of 
T2DM. 
 
Non-etiologic treatment 
HCV-T2DM requires [205] various measures including: lifestyle changes, regular diabetes 
screening, analysis of other risk factors accelerating both CHC and DM, such as obesity, 
dyslipidemia, and alcohol consumption. Early identification and treatment of IR or T2DM 
reduce liver disease progression [206], incidence of HCC, transplant-related morbidity 
and mortality, and improve the AVT response [191, 207], minimizing side effects [200]. 
Therapeutic options in HCV-T2DM include diet changes, anti-diabetic drugs, statins. Itis 
not clear whether the best approach is a peroxisome proliferator-activated receptor 
(PPAR) agonist or a biguanide such as metformin [208-210]. Prospective, randomized 
controlled trials showed increased SVR using metformin in HCV patients with IR 
receiving AVT [211]. Different analyses that evaluated metformin use in these patients 
showed a significant reduction of HCC, liver-related death, and liver transplant with an 
increased survival rate [211]. Concerning statins, the inhibition of HCV replication was 
shown in vitro [128], but not in vivo [212, 213]. 
 
SICCA SYNDROME/SJÖGREN’S SYNDROME 
The frequent association between sicca syndrome and HCV infection has been shown by 
both experimental and epidemiological studies [160, 214, 215]. Sicca syndrome related 
symptoms have been reported in 20% to 30% of HCV patients, whereas less than 5% of 
patients with a defined Sjögren’s syndrome are HCV-positive [216]. Although low titers of 
antinuclear antibodies and RF are common in patients with HCV-related sicca syndrome, 
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the presence of primary Sjögren’s syndrome related autoantibodies (anti-SSA/SSB) is 
uncommon.  
Similarities exist between HCV-related sicca syndrome and “true” primary Sjögren’s 
syndrome. , However, HCV-positive sicca syndrome patients are older and more likely to 
have photosensitivity and CV than patients with primary Sjögren’s syndrome [217]. 
Patients with CV may develop a mild sicca syndrome in the absence of typical 
histopathological and/or serological alterations. In some cases the differential diagnosis 
between primary Sjögren’s syndrome and CV may be very difficult, mainly in patients 
with overt sicca syndrome, cryoglobulinemia, and HCV infection [218]. 
 
Etiologic treatment 
IFN-based AVT generally has scarce clinical efficacy, probably because in many cases, 
the onset of symptoms is a consequence of gland destruction. There is no available data 
with IFN free DAAs. 
 
Non-etiologic therapy 
Besides topical treatments that may partially improve HRQoL, there is no specific 
systemic treatment for HCV-associated sicca syndrome [219].  
 
ARTHRITIS 
Arthralgia is common in HCV-infected patients [220] while arthritis is rare (4%-5%) [221, 
222]. Two different subsets of HCV-related arthritis have been identified in some studies 
on limited groups: the more common symmetrical polyarthritis and the intermittent 
mono-oligoarthritis [223-226]. The symmetrical polyarthritis subset shares several 
aspects with rheumatoid arthritis (RA): symmetrical involvement of wrists and hands; 
positive RF in more than 50% of patients, and increased inflammation markers. 
However, the course of HCV related symmetrical polyarthritis is less aggressive when 
compared with RA, typically non-deforming and not associated with articular bone 
erosions; rheumatoid nodules were never reported [227, 228]. Anti-CCP antibodies can 
be helpful in the differential diagnosis between HCV related symmetrical polyarthritis 
and RA because they are rarely detected in the former and almost constant in the latter 
[229, 230]. The intermittent mono-oligoarthritis subset  typically involves the medium 
and large joints of the lower limbs, mainly the ankles [227, 228]. Its course is usually 
acute, with frequent relapses. The intermittent mono-oligoarthritis subset is closely 
related to cutaneous and laboratory manifestations of CV. Intermittent mono-
oligoarthritis flares frequently  occur simultaneously to skin flares of CV.  
 
Etiologic treatment 
It has been suggested that, once the diagnosis of HCV-associated arthritis is made, AVT 
can be taken into account. PegIFN plus RBV AVT has been successfully used [19, 225, 
231], but it can promote the worsening of arthritis in others [232]. Therefore, it is 
conceivable that IFN-free regimens will be more useful. 
 
Non-etiologic treatment 
Anti-TNF agents are safe in patients with concomitant HCV infection and classical RA 
[233], but their use appears generally excessive. Therapeutic approaches to HCV-related 
arthritis remains largely empirical, because few studies have been published. Usually, 
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HCV-related arthritis patients may respond to low doses GCs and hydroxychloroquine. 
Concerns may be raised regarding the use of immunosuppressive or potentially 
hepatotoxic drugs, in particular methotrexate and leflunomide, often not necessary or 
contraindicated. On the contrary, RTX may be successfully employed, mainly in patients 
with more aggressive disease, and may represent the first-choice treatment in patients 
with arthritis in the setting of CV [234]. 
 
3.8. MISCELLANEA  
For other HCV-EHMs, data about the effect of viral eradication (representing the most 
important argument in favor of a true etiopathogenetic association) are too scarce or 
absent. Some of these can represent either EHMs or side-effects of AVT or consequences 
of advanced liver damage, making frequently difficult their exact attribution. These latter 
include pruritus, psoriasis and other skin disorders. Other cases, like urticaria, have 
been only suspected to be associated with HCV, due to the existence of both limited and 
discordant data. 
 
 
4. DISCUSSION 
We recently formed an International Study Group of Extrahepatic Manifestations related 
to HCV (ISG-EHCV) with the aim to provide a homogeneous clinico-diagnostic [19] and 
therapeutic approach to HCV patients presenting with HCV-EHMs through the 
development of a multidisciplinary international network of experts. 
This paper summarizes recommendations about a new hot and discussed topic in the 
managing of HCV infection: the therapeutic approach to various extrahepatic diseases 
more or less directly linked to this infection. HCV-EHMs have been shown to be 
responsible for significantly higher mortality/morbidity rates when compared with non-
infected (or no more infected) subjects [6], with important consequences in terms of 
social costs. 
The present recommendations are based only on scientific criteria and do not take into 
account the debated issue related to the cost/benefit ratio, which is also a concern, 
especially in some regions of the world. 
In each HCV-EHM, the actual pathogenic role played by the virus was evaluated in order 
to better understand the opportunity and urgency to use AVT. In turn, the possibility to 
completely eradicate the infection, appears crucial to better evaluate such a role (“ex 
adiuvantibus criterium”). For disorders, like the HCV-related LPDs, the effect of viral 
eradication represents the stronger proof of the etiopathogenetic involvement of HCV 
[23]. In this light, however, the former IFN-based etiologic therapy frequently provided a 
uncertain “ex adiuvantibus” picture, due to indirect immunomodulatory effects of IFN, 
especially in studies with a short follow-up. The availability of drugs directly acting on 
the virus in IFN-free combinations led to minimize or abolish (in both IFN- and RBV-free 
regimens) such immunomodulatory effects. Furthermore, their safety promises to allow 
the HCV eradication also in patients previously intolerant with severe HCV-EHMs. On 
the other hand, it is conceivable that, in some cases, the positive effects on HCV-EHMs 
(improvement or resolution) at the end of treatment and in the early post treatment 
period, will be less evident compared to IFN-based AVT. Available, although limited data, 
obtained in HCV LPDs like CV and NHL [125] seem to be in agreement with this 
hypothesis, suggesting the opportunity  for a longer follow-up. Another confirmation 
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arises from the observation of a paradoxical improvement of some HCV-EHMs despite of 
HCV persistence (virologic non-response), observed after IFN-based regimens and usually 
transient [17]. The availability of drugs without immune-modulatory properties, makes 
also easier the decision to treat patients with autoimmune disorders and uncertain viral 
etiopathogenesis, thus at risk of worsening after an IFN-based therapy. The availability of 
IFN-free AVT support the recommendation to eradicate, as soon as possible, a virus 
known to strongly sustain B-cell activation and with lymphomagenetic potential. In other 
words, IFN-free AVT should be a priority in HCV-positive autoimmune and/or 
lymphoproliferative disorders, even if the liver damage is not severe. 
The urgent need of clear and easy-to-use therapeutic guidelines, comes from this specific 
aspect in managing a patient with EHMs. The hepatologist has to be advised that a 
counseling with a specialist may be not sufficient, because both physicians should 
recognize a new systemic pathological entity generated by the infection, the so-called 
HCV-disease [19]. In more details, the therapeutic approach could not be referred to 
specialist guidelines for each specific manifestation/symptom, but should take into 
account the strong impact on all the aspects of HCV infection. This should happen not 
only when the probability is high that HCV is the causal agent of an EHM (as it is for 
HCV-CV), but also when the virus is only a trigger (as for HCV-PCT).  
The exchange of information between different specialists has to aim at evaluating the 
pros and contras of different interventions and their timelines. An exemplary case is 
represented by situations requiring a non-etiologic priority approach (i.e. rapidly evolving 
HCV-EHMs or, conversely, in absence of national health care reimbursement as 
presently in some countries. Another example is given by difficult-to-treat cases for 
patient’s characteristics (i.e. advanced cirrhosis in an experienced patient previously not 
responsive to AVT) and/or for the virus (i.e. HCV genotype 3). Usually, in these 
conditions, RBV is indicated to increase the chances of viral eradication, but it is 
contraindicated or should be used cautiously for some EHMs (i.e. in presence of ischemic 
damage, significant renal damage, PCT). 
Non etiologic therapies also need a close collaboration between specialists of different 
medical areas: i.e. to manage patients with co-morbidities requiring a chronic 
administration of drugs potentially interacting with some DAAs. This means that it is 
important to agree on tailoring both the AVT and the other therapies possibly 
rescheduling one and/or making appropriate changes with non-interfering alternative 
drugs. Dedicated websites could support and help the health care providers in this kind 
of decision. 
The critical point is therefore a wider and multidisciplinary spreading of the knowledge 
about HCV-EHMs, in order to provide a more conscious and aware approach.  The 
present recommendations are designed to address this need. They mean to briefly recall 
to non-specialists, the essential features of the different manifestations of the HCV 
disease in order to provide the best intervention in terms of etiologic and/or non-etiologic 
(pathogenetic-symptomatic) treatments.. This would be the necessary basis for future 
modifications according to available new data. 
In conclusion, although the hope for a definitive cure for the HCV EHMs seems to 
be closer than ever, the complexity of these patients in whom different etiopathogenic 
scenarios are coexisting (autoimmune, metabolic, neoplastic) anticipate a more difficult 
therapeutic scenario than that is now reported in the standard HCV infected patients’ 
population. 
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In other words, with this work we would like to provide patients, health care 
practitioners and specialists of the referral centers proper information on the structured 
and comprehensive management of patients with a complex pathological entity, the HCV 
disease. 
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BOX=  TAKE-HOME MESSAGES 
 
ANTIVIRAL (ETIOLOGIC) TREATMENT OF HCV-EHMs 
 
• IFN-free, DAA-based antiviral therapy should be considered a first line therapeutic 
measure for HCV-EHMs that does not need urgent/life threatening measures  
• All patients with HCV-EHMs without short life expectancy due to non HCV-related 
comorbidities should be considered for treatment 
• When universal treatment may not be scaled up, HCV-EHMs should be considered 
a prioritization criterion  
• The first target of etiologic therapy is the HCV eradication and consequent HCV-
EHM improvement 
• The degree of HCV-EHM clinical improvement depends on the degree of 
reversibility of the HCV-induced damage  and / or the underlying  pathogenic process : 
early viral eradication is recommended 
• IFN-free DAA treatment of HCV-EHMs, should follow general criteria standardized 
for the treatment of HCV infection, accurately taking into account the HCV-EHMs 
characteristics 
• Both IFN- and RBV-free DAA therapy should be preferred in patients with kidney 
disease, PCT, ischemic tissue lesions (i.e., skin ulcers, ischemic heart disease), anemia 
(i.e., in LPDs) 
• Therapy of kidney disease imply a careful approach, including accurate evaluation 
of the kidney damage and choice of DAA treatment and follow-up schedule  
• Using IFN-free DAA therapy, the possible “rebound effect” of abrupt withdrawn of 
non-etiologic therapy should not be interpreted as DAAs  side effect 
 
NON ANTIVIRAL (NON ETIOLOGIC) TREATMENT OF HCV-EHMs 
 
• Non-etiologic therapy is  the  first line treatment in case of HCV-EHMs needing 
urgent/life threatening  measures, but should be useful  also in less severe cases before, 
during  or  after antiviral therapy in patients with persistent disease 
• The combination of IFN-free DAA and non-etiologic therapy  can  be allowed, 
especially  in severe cases 
• Persistence after antiviral therapy of immunological/laboratory abnormalities (i.e., 
cryoglobulinemia) in the absence of any clinically evident disease, does not justify 
therapy  
• The choice of  non-etiologic therapy should  always take into account the degree of 
HCV-related liver damage and, in case of DAAs co-administration, the possible drug-drug 
interactions 
• In clinically  moderate-severe autoimmune/lymphoproliferative HCV-EHMs 
(especially cryoglobulinemic vasculitis) with failure or contraindication  to antiviral 
treatment, Rituximab should be considered   a first line therapeutic measure.  Combined 
treatment can be  indicated 
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International Study Group of Extrahepatic Manifestations Related to Hepatitis C Virus 
Infection (ISG-EHCV): 
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Hopital La Pitié Salpêtrière 
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Departement Hospitalo-Universitaire I2B 
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Université Pierre Marie Curie, Paris 6. 
 
tel. + 33 1 42 17 80 27; fax + 33 1 42 17 80 33 
 
E-mail: patrice.cacoub@psl.aphp.fr 
 
Milvia Casato 
 
Department of Clinical Immunology, 
 
Sapienza University of Rome, Viale dell'Università 37, 
 
00185 Rome, Italy 
 
E-mail: milvia.casato@uniroma1.it 
 
Clodoveo Ferri 
 
Chair and Rheumatology Unit, 
 
Medical School, University of Modena and Reggio Emilia, 
 
zienda Ospedaliero-Universitaria, Policlinico di Modena, 
 
41124 Modena, Italy 
 
E-mail: clferri@unimore.it 
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Peter Lamprecht 
Department of Rheumatology & Vasculitis Center, University of Lübeck, Ratzeburger 
 Allee 160, 23538 Lübeck, Germany, Tel.: ++49 (0)451500 2368,Fax: ++49 (0)451500  
3650, E-mail: peter.lamprecht@uksh.de 
Alessandra Mangia 
 
Liver Unit, IRCCS “Casa Sollievo della Sofferenza”, 
 
San Giovanni Rotondo, Italy. 
 
a.mangia@tin.it 
 
Manuel Ramos-Casals 
 
Department of Autoimmune Diseases 
 
Josep Font Laboratory of Autoimmune Diseases 
 
Hospital Clinic CELLEX-IDIBAPS 
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Tel: + 34-932275774; Fax: + 34-932271707 
 
E-mail: mramos@clinic.ub.es 
 
David Saadoun 
 
Department of Internal Medicine and Clinical Immunology 
 
Hopital La Pitié Salpêtrière 
 
83 Boulevard de l'hopital 
 
75013 Paris, FRANCE 
 
UMR 7211 (UPMC/CNRS), UMR S-959 (INSERM) 
 
Université Pierre Marie Curie, Paris 6. 
 
tel. + 33 1 42 17 80 27; fax + 33 1 42 17 80 33 
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E-mail: david.saadoun@psl.aphp.fr 
 
Athanasios G Tzioufas 
 
Director Department of Pathophysiology 
 
School of Medicine University of Athens 
 
75 M. Asias st, Building 16, Room 32 
 
11527 Athens, Greece 
 
E-mail: agtzi@med.uoa.gr 
 
Zobair M Younossi 
 
Chairman, Department of Medicine, Inova Fairfax Medical Campus 
 
Vice President for Research, Inova Health System 
 
Professor of Medicine, VCU-Inova Campus 
 
The Claude Moore Health Education and Research Center 
 
Beatty Center for Integrated Research 
 
3300 Gallows Road, Falls Church, VA 22042, USA 
 
Telephone 703-776-2540; Fax 703-776-4388 
 
E-mail: Zobair.Younossi@inova.org 
 
 
Anna Linda Zignego; MD, Ph.D 
 
Professor of Medicine, Interdepartmental Center MaSVE 
 
Department of Experimental and Clinical Medicine 
 
Medical School, University of Florence 
 
Largo Brambilla, 3 50134 Firenze, Italy. 
 
Tel: + 39055 2758086; Fax: + 39055 7947335 
 
E-mail: annalinda.zignego@unifi.it  
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Dr. Anne Claire Desbois, MD, Research fellow, Université Pierre et Marie Curie, Paris 
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Dr. Cloe Commarmond, MD, Research fellow, Université Pierre et Marie Curie, Paris 
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Prof Oliver Hermine, Hematologist, Université Paris Descartes, Paris 
(olivier.hermine@nck.aphp.fr) 
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Dr. Laura Gragnani, Research Fellow Interdepartmental Center MaSVE Department of 
Experimental and Clinical Medicine, University of Florence, Florence, Italy 
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Prof. Alberto Bosi, Hematologist, University of Florence (alberto.bosi@unifi.it) 
 
Prof. Marco Matucci Cerinic, Rheumatologist, University of Florence 
(marco.matuccicerinic@unifi.it) 
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Prof. Luca Arcaini, Department of Molecular Medicine, University of Pavia & Department 
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dario.roccatello@unito.it 
 
Dr. Marcella Visentini, Research fellow, Sapienza University of Rome 
(marcella.visentini@uniroma1.it) 
 
Dr. Alessandro Pulsoni, Hematologist, Sapienza University of Rome 
(pulsoni@bce.uniroma1.it) 
 
Dr. Adriano De Santis, Hepatologist, Sapienza University of Rome (adsdmc@tin.it) 
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Prof. Gregory Hatzis, Hepatologist, University of Athens 
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Dr. Sandra Muñoz, Rheumatologist, Centro Médico Nacional 20 de Noviembre, ISSSTE, 
México DF (ssanml@yahoo.com.mx) 
 
Dr. Francisco Medina, Rheumatologist, Hospital de Especialidades, Centro Médico 
Nacional Siglo XXI, Mexico DF (fmedina_99@yahoo.com) 
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(luis_jara_quezada@hotmail.com) 
 
Dr. Mario García-Carrasco, Rheumatologist, Systemic Autoimmune Diseases Research 
Unit, IMSS, Puebla, México Department of Rheumatology and Immunology, Benemérita 
Universidad Autónoma de Puebla, Puebla, México (mgc30591@yahoo.com) 
 
Prof. Munther Khamashta, Internist & Rheumatologist, Dubai Hospital, Dubai, United 
Arab Emirates (munther.khamashta@kcl.ac.uk) 
 
Prof. Yehuda Shoenfeld, Head Zabludowicz Center for Autoimmune Diseases, Sheba 
Medical Center, Tel-Hashomer, Israel (Yehuda.Shoenfeld@sheba.health.gov.il) 
 
Prof. John H. Stone, Harvard Medical School, Boston, MA, US (jhstone@partners.org) 
 
Dr. Soledad Retamozo, Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina 
(soleretamozo@hotmail.com) 
 
Prof. Chien-Jen Chen, National Taiwan University, Nankang, Taipei 11529, Taiwan 
(cjchen@ntu.edu.tw) 
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Table 1. Main adverse event of second-wave DAAs 
 
PROTEASE INHIBITORS  
Simeprevir 
-Photosensitivity 
-Contraindicated in cirrhosis (Child-Pugh B or C) 
-Hyperbilirubinaemia 
Paritaprevir (boosted with ritonavir) 
-Drug-drug interactions (due to ritonavir) 
-Contraindicated in cirrhosis (Child-Pugh B or C) 
-Hyperbilirubinaemia 
-Hypertransaminasemia 
Grazoprevir -Well tolerated 
NS5A INHIBITORS  
Ledipasvir 
-Well tolerated 
-Some drug-drug interactions (with acid suppressants) 
Ombitasvir -Well tolerated 
Daclatasvir -Well tolerated 
Elbasvir -Well tolerated 
NS5B INHIBITORS 
 
Sofosbuvir 
-Contraindicated in severe renal impairment (estimated 
GFR less than 30ml/min) 
-Some drug-drug interactions (with amiodarone) 
Dasabuvir -Well tolerated 
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Table 2. Individual health criteria for prioritization in case of HCV extrahepatic manifestations 
 
 EASL* WHO** AASLD/IDSA*** 
Metabolic syndrome No specific indications Prioritized No specific indications 
Cryoglobulinemia vasculitis Prioritized Prioritized No specific indications 
Lymphoproliferative disorders Prioritized Prioritized No specific indications 
Renal disease Prioritized Prioritized No specific indications 
Debilitating Fatigue Prioritized Prioritized No specific indications 
Significant psychosocial morbidity No specific indications Prioritized No specific indications 
 
*European Association for the Study of the Liver (EASL) Recommendations, 2016; 
http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/easl-
recommendations-on-treatment-of-hepatitis-c-2016    
**WHO: World Health Organization: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-
guidelines/en/   
***AASLD/IDSA: American Association for the Study of Liver Disease (AASLD)/ Infectious 
Diseases Society of America (IDSA): No specific indications: “Treatment is recommended 
for all patients with chronic HCV infection, except those with short life expectancies that 
cannot be remediated by treating HCV, by transplantation, or by other directed therapy” 
http://www.hcvguidelines.org/full-report-view  
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Table 3. Interferon-related treatment of cryoglobulinemic vasculitis 
refer.
n° 
Author Year n° patients Treatment CS 
Treatment 
duration 
(months) 
Virological response Clinical response° 
EOT Sustained EOT Sustained 
28 Ferri 1993 26 
2 MIU IFN/d (1m) → 2 MIU IFNx3/w 
(5m) 
yes 6 13% n.a. 1 n.a. 
13 Ferri 1993 15 
2 MIU IFN/d (1m) → 2 MIU IFNx3/w 
(4m) 
yes 5 8% n.a. 93% n.a. 
29 Marcellin 1993 2 3 MIU IFNx3/w n.a. 6 0% n.a. 50% 0% 
30 Johnson 1993 4 1-10 MIU IFN no 2-12 100% 75% 75% n.a. 
235 Zimmermann 1993 1 3 MIU IFNx3/w no 3 n.a. n.a. Worsening n.a. 
236 Bojic 1994 1 
3 MIU IFNx2/w (4w) → 3 MIU IFNx3/w 
(2w) 
no 6 w n.a. n.a. Worsening n.a. 
14 Misiani 1994 27 
1.5 MIU IFNx3/w (1w) → 3 MIU 
IFNx3/w (23w) 
no 6 60% 0% 6/7 0% 
49 Dammacco 1994 
15 
17 
3 MIU IFNx3/w 
3 MIU IFNx3/w 
no 
yes 
12 
12 
42% 
50% 
17% 
14% 
53% 
53% 
13% 
18% 
237 Johnson 1994 8 3 MIU IFNx3/w no 6-12 n.a. n.a. 75% n.a. 
238 Mazzaro 1994 18 (5 NHL) 3 MIU IFNx3/w no 12 44% 22% 
28% complete 
50% partial 
Clinical resp    
CGs pos 
239 Gilli 1996 1 3 MIU hIFN-αx3/w no 10 1(100%) 1(100%) 1(100%) 1(100%) 
240 Harle 1995 1 3 MIU IFNx3/w no 
2 w 
(5 injections) 
n.a. n.a. Worsening n.a. 
241 Mazzaro 1995 
18 
18 
(8 NHL) 
3 MIU IFNx3/w 
3 MIU IFNx3/w 
 
no 
no 
 
6 
12 
 
44% 
50% 
 
11% 
22% 
 
28% 
39% 
 
11% 
22% 
 
242 Migliaresi 1995 18 3 MIU IFNx3/w no 12 n.a. n.a. 72% 28% 
243 Yamabe 1996 1 
10 MIU IFN/d (2 w) → 10 MIU IFNx3/w 
(6 w) 
no 2 1 (100%) 1 (100%) 
Clinical resp 
CGs pos 
Clinical resp 
 CGs pos 
244 Casaril 1996 36 6 MIU IFNx3/w no 6 n.a. n.a. 31% 19% 
245 Cohen 1996 16 3 MIU IFNx3/w variable 6 n.a. n.a. 56% 0% 
15 Adinolfi 1997 50 3 MIU IFNx3/w no 12 n.a. n.a. 44% 12% 
246 Sarac 1997 1 
3 MIU IFNx3/w (6 m) → 10 MIU IFN/d 
(2 w) → 10 MIU IFNx3/w (6 w) 
no 8 1 (100%) 1 (100%) 1 (100%) CGs pos 
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247 Zuber 1997 2 
Pt. 1: 3 MIU IFNx3/w 
Pt. 2: 3 MIU IFNx3/w (3 m) → 6 MIU 
IFNx3/w (7 m) → 3 MIU IFNx2/w 
no 
no 
 
2.5 
n.a. 
 
1(100%) 
0% 
 
n.a. 
n.a. 
 
1(100%) 
(reduced cryocrit) 
 
0% 
n.a. 
 
248 Akriviadis 1997 20 3-5 MIU IFNx3/w no 6-12 n.a. n.a. 65% 20% 
249 Casato 1997 31 
3 MIU IFN/d (3m) → 3 MIU IFNx3/w 
(>9m) 
no >12 n.a. 11/23 (48%) 55% 29% 
250 Mazzaro 1997 42 (7 NHL) 3 MIU IFNx3/w no 12 n.a. 14% 31% 14% 
251 Donada 1998 
13 Rel 
4 NR 
6 MIU IFNx3/w (3 m) →3 MIU IFNx3/w 
(3 m) + RBV (6 m) 
no 6 
85% 
0% 
38% 
0% 
n.a.** 38.5% 
252 Durand 1998 5 NR RBV no 10-36 0% 0% 
4 improvement 
1 stabilization 
n.a. 
253 Gordon 1998 1 1.5 MIU IFNx3/w yes 
1 w 
(2 injections) 
n.a. n.a. Worsening n.a. 
254 Scelsa 1998 2 
Pt 1: 3 MIU IFNx3/w (1 m) → 
prednisone → 1 MIU IFNx3/w 
Pt. 2: 3 MIU IFNx3/w 
yes 
 
yes 
6 
 
3 injections 
n.a. n.a. 
Worsening of 
polyneuropathy 
n.a. 
255 Calleja 1999 
18  
 
8 NR 
5 Rel 
3 MIU IFNx3/w 
 
3 MIU IFNx3/w +RBV (retreatment) 
3 MIU IFNx3/w+RBV (retreatment) 
no 
 
no 
no 
12 
 
12 
12 
55% 
 
62% 
100% 
27% 
 
37.5% 
80% 
55% 
 
62% 
100% 
27% 
 
37.5% 
80% 
256 Cid 1999 3 3 MIU IFNx3/w yes 2-4 n.a. n.a. 
Worsening of ischemic 
lesions 
n.a. 
257 Cresta 1999 43 3 MIU IFNx3/w no 6 42% 14% 40% 14% 
258 Friedman 1999 1 3 MIU IFNx3/w no 3 w n.a. n.a. Exitus n.a. 
259 Misiani 1999 1 3 MIU IFNx3/w+RBV (4 m) no 16 100% 100% 100% 100% 
48 Mazzaro 2000 7 (2 NHL) 3 MIU IFNx3/w no 6 29% 14% 14% 14% 
225 Zuckerman 2000 9 3 MIU IFNx3/w +RBV no 6 22% 22% 78% 56% 
260 Garini 2001 2 
Pt. 1: 3 MIU IFNx3/w+RBV 
Pt. 2: 3 MIU IFNx3/w+RBV 
no 
6 
12 
1 (100%) 
1 (100%) 
1 (100%) 
n.a. 
1 (100%) 
CGs pos 
1 (100%) 
n.a. 
261 Naarendorp 2001 10 3 MIU IFNx3/w no 3-60 n.a. n.a. n.a.*** n.a.*** 
262 Beddhu 2002 10 
3 MIU IFNx3/w 
4 pts.NR retreated with: 10 MIU/d (2 w) 
→ 10 MIUx3/w (6 w) 
no 
12 
2 
 
n.a. 
n.a. 
 
10% 
25% 
 
10% 
50% 
 
10% 
50% 
 
35 Cacoub 2002 14 Variabile IFN+RBV variable 6-56 n.a. 64% n.a. 10/14  
263 Casato 2002 1 
3 MIU IFN/d → 3 MIU IFNx3/w → 3 
MIU IFN/d 
no 18 0% 0% Remission n.a. 
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264 
Loustaud-
Ratti 
2002 2 
Pt. 1: 3 MIU IFNx3/w 
3 MIU IFNx3/w+RBV (retreatment) 
Pt. 2: 3 MIU IFNx3/w → plus RBV 
no 
no 
yes 
12 
12 
12 
1 (100%) 
1 (100%) 
1 (100%) 
0% 
1 (100%) 
1 (100%) 
1 (100%) 
1 (100%) 
1 (100%) 
0 % 
1 (100%) 
1 (100%) 
265 Sikaneta 2002 1 OLT 2 MIU IFNx2/w+RBV → Peg-IFN+RBV yes 10 
n.a. (neg in 
treatment) 
- n.a.(neg in treatment) n.a. 
266 Bruchfeld 2003 2 
Pt. 1: 3 MIU IFNx3/w+RBV 
Pt. 2: Peg-IFN+RBV 
yes 
no 
6 
6 
1 (100%) 
1 (100%) 
0% 
1 (100%) 
1 (100%) 
1 (100%) 
vasculitis flare 
1 (100%) 
36 Mazzaro 2003 
27 (3NHL) 
NR or Rel. 
3 MIUx3/w+RBV no 12 5/24(21%) 5/24(21%) 
15 immunol. resp 19 
clinical resp (transient)  
5/24 (21%) 
267 Rossi 2003 3 RBV (4 w) → 3 MIU IFNx3/w+RBV no 13 3 (100%) 3 (100%) 3 (100%) 3 (100%) 
268 Alric 2004 18 
3 MIUx3/w+RBV (n=14) or Peg-
FN+RBV (n=4) 
variable 6-24 72% 66.6% n.a. n.a. 
269 Batisse 2004 1 Peg-IFN no 1 0% 0% worsening n.a. 
270 Cacoub 2005 9 Peg-IFN 1.5ug/Kg/w+RBV variable 10-26 89% 78% 100% 88%°° - 56%°°° 
271 Levine 2005 4 
Pt. 1: Peg-IFN+RBV 
Pt. 2: IFN 
Pt. 3: Peg-IFN+RBV 
Pt. 4: IFNx3/w+RBV 
no 
no 
no 
no 
6 
18 
12 
12 
1(100%) 
1(100%) 
1(100%) 
1(100%) 
1(100%) 
1(100%) 
1(100%) 
1(100%) 
no 
CGs increase 
CGs increase 
CGs pos 
n.a. 
272 Mazzaro 2005 18 Peg-IFN 1ug/Kg/w+RBV no 12 83% 44% 
89% complete 
11% partial 
44% 
273 Vigani 2005 1 3 MIU IFNx3/w+RBV no 48 1(100%) 1(100%) 
MCS resp 
CGs pos 
n.a. 
274 Saadoun 2006 72 (9 NHL) 
3 MIU IFNx3/w+RBV (32 pts) 
Peg-IFN+RBV (40 pts) 
variable ≥6 
63% 
75% 
53% 
63% 
47%°° - 28%°°° 
73%°° - 60%°°° 
56%°° - 31%°°° 
68%°° - 58%°°° 
34 Garini 2007 4 
Pt. 1: 3 MIU IFNx3/w+RBV 
Pt. 2: 3 MIU IFNx3/w+RBV 
Pt. 3: Peg-IFN+RBV 
Pt. 4: Peg-IFN+RBV 
no 
no 
prior 
no 
6 
12 
12 
12 
1(100%) 
1(100%) 
1(100%) 
0% 
1(100%) 
n.a. 
1(100%) 
- 
1(100%) 
CGs pos 
1(100%) 
Partial resp 
1(100%) 
n.a. 
1(100%) 
Rel 
33 Montalbano 2007 1 Peg-IFN+RBV no 12 1(100%) 1(100%) CGs pos n.a. 
275 Parise 2007 31 3 MIU IFNx3/w+RBV n.a. 6-12 n.a. 29% 32% n.a. 
31 Joshi 2007 
38  
(treatments=47) 
- IFN (8) 
- Peg-IFN (5) 
- Consensus IFN (2) 
- IFN+RBV (18) 
- Peg-IFN+RBV (14) 
no 6-12 n.a. 
25% 
0% 
50% 
17% 
71% 
n.a. 
62.5% 
40% 
50% 
72% 
71% 
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IFN: interferon; Peg-IFN: pegylated-interferon; RBV: ribavirin; BOC: boceprevir; TPV: telaprevir; SOF: sofosbuvir; MIU: millions of international units; d: day; m: 
months; w: weeks; n.a.: not available; pt: patient;  CS: corticosteroids; EOT: end of treatment; NR: non responder/s; Rel: relapser/s; CGs: cryoglobulins; MCS: Mixed 
Cryoglobulinemia Syndrome; NHL: Non-Hodgkin’s Lymphoma; immunol: immunological; resp: response; pos: positive; neg: negative. 
 
** Significant reduction of cryocrit values (transient in relapsers and persistent in sustained virological responders) 
276 Koziolek 2007 1 
(Peg-IFN+RBV → Peg-IFN) + 
cryoprecipitate apheresis 
yes >6 1(100%) n.a. 1(100%)  n.a. 
277 Trebst 2007 1 Peg-IFN+RBV (14 m) → Peg-IFN (4 m) no 18 0% n.a. 100% n.a. 
278 De Blasi 2008 1 Peg-IFN+amantadine no 4 1 (100%) 1 (100%) 
CGs  increase  
 MCS symptoms 
n.a. 
279 Landau 2008 49 (9 NHL) Peg-IFN+RBV n.a. >6 n.a. 59.2% n.a. 69.4% 
32 Landau 2008 8 (3 NHL) IFN+RBV or Peg-IFN+RBV  n.a. 12-25 n.a. 100% 100% 0% 
16 Mazzaro 2011 86 Peg-IFN+RBV n.a. 6-12 72% 50% n.a. 88.5% 
280 Donato 2013 1 OLT Peg-IFN+RBV (8 m) → IFN+RBV (4 m) yes 12 1 (100%) 1 (100%) 1 (100%) 1 (100%) 
281 Saadoun 2014 23 
Peg-IFN+RBV+BOC (8) 
Peg-IFN+RBV+TPV (15) 
variable 12 69.6% n.a. 56.5% n.a. 
282 De Nicola 2014 1 Peg-IFN+RBV+TPV n.a. 12 1 (100%) 1 (100%) 1 (100%) 1 (100%) 
39 Gragnani 2014 22 Peg-IFN+RBV+BOC no 12 n.a. 23.8% n.a. 0% 
40 Stine  2014 3 Peg-IFN+RBV+SOF n.a. 3 100% n.a. n.a. n.a. 
60 Urraro 2015 1 RTXPeg-IFN+RBV+BOC no 10 1(100%) 1(100%) n.a. 1(100%) 
38 Saadoun 2015 30 
Peg-IFN+RBV+BOC (13) 
Peg-IFN+RBV+TPV (17) 
variable 12 n.a. 20 (66.7%) n.a. 
66.7%°° - 
33.3%°°°° 
17 Gragnani 2015 121 Peg-IFN+RBV no 6-12 n.a. 52% n.a.  50.4%°° 
41 Cornella 2015 5 
Pt. 1: Peg-IFN+RBV+BOC 
Pt. 2: RTX  Peg-IFN+RBV+TPV   
PEG-IFN+RBV  PEG-IFN+RBV+SOF 
Pt. 3: Peg-IFN+RBV+TPV 
Pt. 4: RTX  Peg-IFN Peg-IFN+RBV  
 Peg-IFN+RBV+SOF 
Pt. 5: RTX  Peg-IFN+RBV+SOF RTX 
(maintenance regimen for low grade 
lymphoma) 
no 
no 
 
no 
yes 
 
no 
 
 
7 
1315 
 weeks 
11 
n.a. 
 
3 
 
 
1 (100%) 
1 (100%) 
 
1 (100%) 
1 (100%) 
 
1 (100%) 
 
 
1 (100%) 
1 (100%) 
 
1 (100%) 
1 (100%) 
 
1 (100%) 
 
 
Partial response 
Clearance of CGs 
 
NR 
NR 
 
CGs clearance 
 
 
Partial response 
Clinical NR 
 
NR 
NR 
 
CGs clearance 
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***Coincidence between sustained virological and clinical response 
°: The clinical response was variably classified in different studies: data are only partially comparable;   
°°: complete clinical response 
°°°: complete immunological response 
°°°°: partial clinical response 
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Table 4. Interferon-free treatment of cryoglobulinemic vasculitis 
 
 
°: The clinical response was variably classified in different studies: data are only partially comparable
refer.
n° 
Author Year n° patients Treatment CS 
Treatment 
duration 
(months) 
Virological response Clinical response° 
EOT Sustained EOT Sustained 
283 Sultanik 2015 1 SOF+RBV until week 4 then SOF+DAC no 3 1(100%) 1(100%) n.a. n.a. 
42 Saadoun 2015 24 SOF+RBV no 6 91.7% 74% 
87.5% complete 
12.5% partial 
86.9% 
43 Sise 2016 12 4 SOF+RBV, 8 SOF+SIM no 3-6 100% 83% n.a. 
33.3% complete  
33.3% partial 
284 Flemming 2016 1 SOF+LEDIPASVIR+RBV no 3 100% 100% n.a. n.a. 
285 Sollima 2016 7 
 Ombitasvir/paritaprevir/ritonavir
+dasabuvir 
 SOF+RBV 
 SOF+DCL 
 SOF+SIM 
no 3-6 100% 100% n.a. 14.3% 
125 Gragnani 2016 44 
 18  SOF+RBV 
 12  SOF+SIM (6 + RBV) 
 4   SOF+DCL (1 + RBV) 
 10 SOF + LED (3 + RBV) 
no 3-6 100% 100% 
25% full complete  
34% complete 
25% partial 
16% non responder 
35% full complete  
41% complete 
24% partial 
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Fig 1: Hypothetical pathogenetic process of lymphoproliferative disorders (LPDs) during 
HCV chronic infection 
 
 
 
 
HCV-related LPDs arise from a cascade of mechanisms and events that progressively 
lead such lymphoproliferation to lose the dependence from the etiologic viral agent (no-
return points).  The prolonged and abnormal B-cell stimulation is sustained by different 
factors: the HCV ability to infect these cells; the E2-CD81 binding, that lowers the 
activation threshold of lymphocytes; a direct action of HCV proteins; the effect of several 
cytokines, first of all the B-cell Activating Factor (BAFF).  
The apoptosis inhibition and the consequent prolonged B-cell survival, could be caused 
by different events, particularly the t(14;18) translocation leading to overexpression of 
the anti-apoptotic protein Bcl-2 together with other genetic mutations.  
It is conceivable that all these mechanisms work on a particular host genetic pattern, 
preparing a favorable background for the onset of HCV-related LPDs. A contribution of 
epigenetic modifications could also take part to this complex pathogenesis. The addition 
of other unknown genetic aberrations, would lead to a frank malignancy that can 
progressively become independent from the viral etiologic agent. 
LPDs: lymphoproliferative disorders; E2: HCV E2 protein; BAFF: B-cell Activating Factor; 
t(14;18): chromosomal translocation (14;18) or Bcl2 gene rearrangement; Bcl-2 (B-cell 
lymphoma 2) gene and protein; NHL: non-Hodgkin’s lymphoma 
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